Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides

Cancer drugs often fail due to the emergence of clinical resistance. This can manifest through mutations in target proteins that selectively exclude drug binding whilst retaining aberrant function. A priori knowledge of resistance-inducing mutations is therefore important for both drug design and cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Siau Jia, Chee, Sharon, Yurlova, Larisa, Lane, David, Verma, Chandra, Brown, Christopher, Ghadessy, Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078010/
https://www.ncbi.nlm.nih.gov/pubmed/27057630
http://dx.doi.org/10.18632/oncotarget.8572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078010/
https://www.ncbi.nlm.nih.gov/pubmed/27057630
http://dx.doi.org/10.18632/oncotarget.8572

Ejemplares similares